Ciudad Real, Spain
Ciudad Real, Spain

Time filter

Source Type

News Article | May 17, 2017
Site: www.prnewswire.com

The seven categories for 2017 are: Law Enforcement/Arson Dogs, sponsored by the K-9 Courage Program™ from Zoetis; Military Dogs, sponsored by the K-9 Courage Program from Zoetis; Therapy Dogs, sponsored by Chicken Soup for the Soul Pet Food, the official pet food of the 2017 Hero Dog Awards; Service Dogs, sponsored by Modern Dog magazine; Emerging Hero Dogs, a category that pays tribute to ordinary dogs who do extraordinary things, sponsored by Boehringer Ingelheim Animal Health, maker of NexGard® (afoxolaner) Chewables; Search and Rescue Dogs; and Guide/Hearing Dogs. Over the past six years, Americans have cast millions of votes for more than a thousand dogs, all seeking the coveted title of American Hero Dog. The program reaches more than one billion people each year and draws the support and participation of top celebrity dog lovers from all over the world. Hosts, judges, award presenters, and entertainment acts have included Katharine McPhee, Alison Sweeney, Bindi Irwin, Derek Hough, Michelle Beadle, Victoria Stilwell, Betty White, Whoopi Goldberg, Denise Richards, Gary Sinise, Burt Reynolds, Chelsea Handler, Martin Short, Jewel, Wilson Phillips, John Ondrasik, Carson Kressley, Miranda Lambert, Pauley Perrette, Kristen Chenoweth, Naomi Judd, Lori Loughlin, Lea Thompson, Eric Stonestreet, Fred Willard, Danica McKellar, Bailee Madison, and many, many more. "For thousands of years, mankind has had a special relationship with dogs, and the American Humane Hero Dog Awards are our way of honoring the best of our best friends," said Dr. Robin Ganzert, American Humane president and CEO. "This unique awards show celebrates the unbreakable human-animal bond, which has been a core part of our organization's mission since 1877." "The Hero Dog Awards recognize some of America's bravest heroes on both ends of the leash," said philanthropist and presenting sponsor Lois Pope. "From those who defend our country to those who help us heal, guide us, protect us, and help find the lost, every single contender exemplifies the courage and heroism we seek to spotlight in this campaign. Our goal is not only to honor these magnificent dogs but to inspire America to reflect on the outsized contributions that animals make in our lives each and every day." Here are brief descriptions, written by the hero dogs' owners/handlers: For more information about the 2017 American Humane Hero Dog Awards®, and to vote daily in the contest, please visit www.herodogawards.org. For more information on sponsorship opportunities email Mari Harner at marih@americanhumane.org  or call 1-800-227-4645. American Humane is the country's first national humane organization, founded in 1877. For more information, please visit www.americanhumane.org. To inquire about Hero Dog Awards sponsorship opportunities, please email Mari Harner at marih@americanhumane.org. About Lois Pope, The Lois Pope LIFE Foundation, Inc., and LIFE (Leaders in Furthering Education) As one of America's leading philanthropists, Lois Pope has positively impacted the lives of individuals at the local, national and international levels.  She has established three separate organizations dedicated to helping those in need.  These organizations are the Lois Pope LIFE Foundation, Inc., Leaders In Furthering Education (LIFE), and the Disabled Veterans' Life Memorial Foundation.  For more than 20 years she has been the driving force behind the Lois Pope LIFE Center at the University of Miami School of Medicine, The American Veterans Disabled for Life Memorial, and a groundbreaking new program with American Humane in Palm Beach County. Lois Pope has recently donated two Lois Pope Red Star Rescue Vehicles. Each rescue vehicle is a 50-foot long response unit, complete with a Ford F-350 truck and trailer, which is specifically designed and outfitted to provide an array of animal emergency services and cruelty responses within the region. Mrs. Pope recently saw the completion of a decade's long dream – the American Veterans Disabled for Life Memorial, which was dedicated by President Obama in Washington, DC on Sunday, October 5, 2014. The Memorial will forever stand as a reminder to the public and legislators of the courage and sacrifices of the four million living disabled veterans and all those who died before them for the need to be vigilant in assuring their support, as well as being aware of the human cost of war. A mother and a grandmother, Lois has trained for and completed five New York City Marathons. Hallmark Channel is Crown Media Family Networks' flagship 24-hour cable television network, distributed nationwide in high definition (HD) and standard definition (SD) to 89 million homes.  As the country's leading destination for quality family entertainment, Hallmark Channel delivers on the 100-year legacy of the Hallmark brand.  In addition to its signature new, original movies, the network features an ambitious lineup of other new, original content, including scripted primetime series, such as "Good Witch," "When Calls the Heart" and "Chesapeake Shores"; annual specials including "Kitten Bowl" and "Hero Dog Awards"; and a daily, two-hour lifestyle show, "Home & Family."  Additionally, Hallmark Channel is the exclusive home to world premiere presentations of the acclaimed Hallmark Hall of Fame franchise.  Dedicated to helping viewers celebrate life's special moments, Hallmark Channel also offers annual holiday programming franchises, including "Countdown to Christmas," "Countdown to Valentine's Day," "Summer Nights," "Fall Harvest" and "Winterfest."  Rounding out the network's diverse slate are some of television's most beloved comedies and series, including "The Golden Girls," "The Middle," "Last Man Standing," and "Frasier." For more information, please visit www.crownmediapress.com  Hallmark Channel on Social Media: Facebook, Twitter, Pinterest, YouTube Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com. About Chicken Soup for the Soul Pet Food Chicken Soup for the Soul understands the unique relationship between people and pets. Health conscious consumers have been feeding their cats and dogs Chicken Soup for the Soul wholesome and balanced, super premium pet food for over a decade. Holistic in nature, the entire line of products is made from only the finest ingredients: real meats (chicken, turkey, duck and salmon), fruits, vegetables and herbs. With no added corn, wheat, soy, artificial coloring, flavoring or preservatives, Chicken Soup for the Soul pet food is inspired by your love for pets, and promotes overall health and well-being for dogs and cats.  The products are proudly made in the USA, and feature rescued shelter pets on every bag. Core and grain-free formulas are available in independent pet specialty stores nationwide and online, with a new line of treats recently launched. A portion of all proceeds from the sale of Chicken Soup for the Soul pet food goes to help shelters and pets in need through Chicken Soup for the Soul's Fill a Bowl … Feed a Soul™ program. The program which was launched in association with the American Humane aims to provide a million meals to shelter pets in 2017. www.chickensouppets.com Modern Dog -- "the best dog magazine ever" and the #1 dog publication in North America -- is a must-read for dog lovers. Your source for the best ideas and solutions for life with dogs, Modern Dog features training tips, insight into your dog's behavior, the best gear, wellness, rescue, DIY how-tos, contests and more! A large part of Modern Dog's mission is to support rescue and the organizations that work tirelessly to help dogs in need. Find Modern Dog online -- www.moderndogmagazine.com -- on newsstands across North America, and on all major social platforms. Modern Dog, your guide to a better bond with your dog! To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/21-remarkable-canines-competing-to-become-americas-top-dog-300459579.html


The global animal health market is expected to reach USD 58.4 billion by 2025 The market is driven by technological advancements in veterinary care, which are anticipated to serve future growth opportunities to the market. For instance, MediLabSecure, a laboratory network project, was initiated with an aim of identifying emerging viruses and pathogens in 19 countries in the Mediterranean regions. In addition, emergence of veterinary health information systems, specifically in the developed economies, is expected to provide high growth potential in future. With the help of these systems, data generated in veterinary clinics can be uploaded on the internet, which can be further shared with other researchers and clinicians. The incorporation of this technology will facilitate real-time analysis of fluctuations in disease prevalence. As a consequence of the aforementioned factors, it is presumed that there will be significant improvement in the overall penetration rate of animal health products, which is also anticipated to fuel the market demand as well as the revenue to unprecedented heights. Further key findings from the study suggest: 3 Animal Health Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.2 Market Driver Analysis 3.2.1 Rising number of government initiatives 3.2.2 Technological advancements 3.3 Market Restraint Analysis 3.3.1 Increasing advent of counterfeit drugs 3.3.2 Lack of standardization 3.4 Penetration & Growth Prospect Mapping 3.5 Animal Health - SWOT Analysis, by Factor (Political & legal, economic and technological) 3.6 Industry Analysis - Porter's For more information about this report visit http://www.researchandmarkets.com/research/vhrc52/animal_health To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-584-billion-animal-health-feed-additives-pharmaceuticals-vaccines-market-forecast-and-trend-analysis-2014---2025---research-and-markets-300457333.html


News Article | May 18, 2017
Site: www.businesswire.com

ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies (Nasdaq: PDCO) today announced that the company will be presenting at two upcoming investor conferences. May 31 – 2017 Stifel Dental & Veterinary Conference in New York City About Patterson Companies Inc. Patterson Companies Inc. (Nasdaq: PDCO) is a value-added distributor serving the dental and animal health markets. Dental Market Patterson’s Dental segment provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America. Animal Health Market Patterson’s Animal Health segment is a leading distributor of products, services and technologies to both the production and companion animal health markets in North America and the U.K.


DUBLIN, May 15, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Animal Health Market Size & Forecast By Product (Feed Additives, Pharmaceuticals, Vaccines), By Animal Type (Production Animal, Companion Animal), By Region (North America, Europe, Asia...


Global Animal Health Partnering Analysis by Deal, Dealmaker and Company for 2010 to 2017 Animal Health Partnering is a unique opportunity to network with industry partners. Every person or the company have specific areas of knowledge and skills wherein they excel. Albany, NY, May 21, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068045 Animal Health Partnering is a unique opportunity to network with industry partners. Every person or the company have specific areas of knowledge and skills wherein they excel. But by partnering and deals with others the overall ability to access more knowledge and capabilities increases. Thus, helping in the betterment of animal health and the related caretaker. The report starts with the introduction of the global animal health partnering terms and agreements as well as the major trends in Animal Health dealmaking. Further, the trends in the Animal Health partnering since 2010 is provided with details of, most active Animal Health dealmakers, partnering by deal type, therapy area & technology type and deal terms for Animal Health partnering. The study provides a detailed review of the leading Animal Health deals since 2010. The top 25 most active Animal Health dealmakers are also listed along with a brief summary of deals announced by that company, as well as contract documents, where available. The report concludes with the partnering resource center with details of online partnering, partnering events and further detailed reading on dealmaking. Moving further, the provided animal health partnering terms and agreements includes, analysis of animal health deal structure, trends in animal health dealmaking in the biopharma industry since 2010, milestone and royalty data, access to headline, upfront, case studies of real-life Animal Health deals, access to animal health contract documents, and most active animal health dealmakers since 2010. Browse Full Report With TOC: http://www.marketresearchhub.com/report/global-animal-health-partnering-terms-and-agreements-2010-to-2017-report.html The key analysis is that the research mainly consist of over 400 online deal records of actual Animal Health deals, as disclosed by the deal parties, and are included towards the end of the report in a directory format by details including, company A-Z, stage of development, deal type, therapy focus, and technology type. In conclusion, the report provides a detailed study of animal health partnering for existing participants as well as potential investors to effectively compete in the market. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Follow us on: Twitter: twitter.com/MktResearchHub LinkedIn: www.linkedin.com/company/market-research-hub Facebook: www.facebook.com/MarketResearchHub/ Albany, NY, May 21, 2017 --( PR.com )-- With the rising awareness about the animal health, nutrition and diagnostic systems, several companies are involved in Animal Health Partnering to provide them better facility, thus are gaining momentum. Considering this fact, Market Research Hub (MRH) has recently evaluated the market and hence presented the result in the report titled as “Global Animal Health Partnering Terms and Agreements 2010 to 2017” to its vast report database. The researched study basically provides a latest Animal Health agreements announced in the life sciences since 2010 along with the major dealmakers and partnering company profiled for the time period 2010-2017.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068045Animal Health Partnering is a unique opportunity to network with industry partners. Every person or the company have specific areas of knowledge and skills wherein they excel. But by partnering and deals with others the overall ability to access more knowledge and capabilities increases. Thus, helping in the betterment of animal health and the related caretaker.The report starts with the introduction of the global animal health partnering terms and agreements as well as the major trends in Animal Health dealmaking. Further, the trends in the Animal Health partnering since 2010 is provided with details of, most active Animal Health dealmakers, partnering by deal type, therapy area & technology type and deal terms for Animal Health partnering. The study provides a detailed review of the leading Animal Health deals since 2010. The top 25 most active Animal Health dealmakers are also listed along with a brief summary of deals announced by that company, as well as contract documents, where available. The report concludes with the partnering resource center with details of online partnering, partnering events and further detailed reading on dealmaking.Moving further, the provided animal health partnering terms and agreements includes, analysis of animal health deal structure, trends in animal health dealmaking in the biopharma industry since 2010, milestone and royalty data, access to headline, upfront, case studies of real-life Animal Health deals, access to animal health contract documents, and most active animal health dealmakers since 2010.Browse Full Report With TOC: http://www.marketresearchhub.com/report/global-animal-health-partnering-terms-and-agreements-2010-to-2017-report.htmlThe key analysis is that the research mainly consist of over 400 online deal records of actual Animal Health deals, as disclosed by the deal parties, and are included towards the end of the report in a directory format by details including, company A-Z, stage of development, deal type, therapy focus, and technology type. In conclusion, the report provides a detailed study of animal health partnering for existing participants as well as potential investors to effectively compete in the market.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.comFollow us on:Twitter: twitter.com/MktResearchHubLinkedIn: www.linkedin.com/company/market-research-hubFacebook: www.facebook.com/MarketResearchHub/ Click here to view the list of recent Press Releases from Market Research Hub


Perrigo's CEO John T. Hendrickson commented, "I am pleased the team was able to complete these filings in an expedited manner. Calendar year 2016 adjusted net sales were $5.2 billion, at the high end of our final guidance range excluding Tysabri®, with continued strong cash flow generation. Strong performance in CHC Americas, steadying business fundamentals in CHC International and improved second half RX pricing visibility led to adjusted diluted earnings per share of $5.07, greater than our final guidance range of $4.70 to $5.00. Our 2017 priorities remain unchanged: focus on the fundamentals of our business through 1) operational execution and efficiency, 2) growth investments in R&D and 3) delivering on our 2017 plan. I am pleased that our consolidated first quarter 2017 top line results were consistent with our plan and continue to anticipate 2017 will be a year of execution to reestablish our foundation, with a projected return to consolidated growth in 2018. We are executing well against our cost optimization plan and the addition of two new directors to our Board further enhances our corporate governance. The quality of this business model remains evident as we continue to advance our strategic action plans and our commitment to providing Quality Affordable Healthcare Products® to customers and consumers around the world." On February 27, 2017, Perrigo issued preliminary unaudited results for calendar year 2016, including preliminary unaudited GAAP EPS loss in a range of $(28.85) to $(29.00), primarily related to goodwill and intangible asset impairment charges of $5.4 billion. The Company also announced preliminary unaudited adjusted diluted EPS in a range of $7.10 to $7.25. The GAAP EPS range for 2016 provided on February 27, 2017 included $62 million of Tysabri® GAAP operating income. This equates to GAAP EPS of $0.38 at the statutory tax rate of 12.5%. Excluding Tysabri®, the February 27, 2017 GAAP EPS range of $(28.85) to $(29.00) changes to a GAAP EPS range of $(29.23) to $(29.38). This final range compares to actual GAAP EPS of $(28.01) realized in calendar year 2016. The adjusted EPS range for 2016 provided on February 27, 2017 included $352 million of Tysabri® adjusted operating income. This equates to adjusted diluted EPS of $2.14 at the statutory tax rate of 12.5%. Excluding Tysabri®, the February 27, 2017 adjusted diluted EPS range of $7.10 to $7.25 changes to an adjusted diluted EPS range of $4.96 to $5.11. This range compares to actual adjusted diluted EPS of $5.07 achieved in calendar year 2016. Refer to Tables I - VII at the end of this press release for a reconciliation of non-GAAP adjustments to the current year and prior year periods and additional non-GAAP information. The Company's reported results are included in the attached Condensed Consolidated Statements of Operations and Balance Sheets. Reported net sales for calendar year 2016 were $5.3 billion, an increase of 5% over calendar 2015. Adjusted net sales for the year were $5.2 billion, an increase of 8% on a constant currency basis over calendar year 2015. New product sales of $311 million were partially offset by $74 million in discontinued products and $58 million of unfavorable foreign currency movements compared to 2015. Reported net sales were also lower due to the completed sale of the U.S. VMS business in the third quarter of 2016. Reported net loss for calendar year 2016 was $(4.0) billion, or $(28.01) per share versus a net loss of $(2) million, or $(0.01) per share, in the prior year. Excluding charges as outlined in Table I at the end of this release, calendar year 2016 adjusted net income was $728 million, or adjusted diluted EPS of $5.07, a year-over-year decrease of 9%. Reported net sales in the quarter were $1.3 billion, a decrease of 2% over the prior year due to the sale of the U.S. VMS business in the third quarter of 2016, which was included in 2015. Adjusted net sales in the quarter were $1.3 billion, an increase of 4%, on a constant currency basis over the fourth quarter of 2015. All reportable segments showed year-over-year growth on an adjusted constant currency basis, led by the CHC Americas segment. New product sales of $69 million were offset partially by $8 million in discontinued products. Reported net loss for the fourth quarter of calendar year 2016 was $(1.4) billion, or $(9.48) per share versus a net loss of $(218) million, or $(1.51) per share, in the prior year. Excluding charges as outlined in Table I at the end of this release, fourth quarter 2016 adjusted net income was $178 million, or adjusted diluted EPS of $1.24, a year-over-year decrease of 11%. Reported net sales in the CHC Americas segment were lower by 3% due to the sale of the U.S. VMS business in the third quarter, which was included in 2015. CHC Americas adjusted net sales, excluding U.S. VMS net sales from the fourth quarter 2015, grew 5% led by an increase in sales of existing products of $41 million (primarily in the infant nutrition, smoking cessation and antacids categories). New product sales in the quarter were $27 million, which included the store brand launches of Flonase® and specific products within the Mucinex® family. These increases were offset partially by a decrease in sales of existing products of $28 million (primarily due to price erosion in certain OTC categories) and discontinued products of $6 million. The CHC Americas segment achieved fourth quarter 2016 reported gross profit margin of 33.5%, an increase of 140 bps over the prior year, and adjusted gross profit margin of 35.5%, an increase of 150 bps over the prior year driven by product mix and supply chain and manufacturing efficiencies. This increase was offset partially by price erosion in certain OTC categories as compared to the prior year. Reported operating margin decreased 110 bps to 13.3%, which was impacted by a $27 million goodwill impairment charge primarily related to the Animal Health business. Adjusted operating margin increased 270 bps to 22.2% on higher gross profit and lower selling and administrative expenses. Reported net sales decreased 3% over the fourth quarter of 2015 due to negative foreign currency movements. Net sales on a constant currency basis grew 3% in the fourth quarter of 2016. The increase in net sales on a constant currency basis was due to greater sales in the Belgium distribution business than in 2015 and new product sales of $26 million. These increases were offset partially by a decrease in sales of existing products of $14 million. Fourth quarter reported gross margin was 36.1% while adjusted gross margin was 41.9%. Gross margin was impacted by greater sales in the lower margin Belgium distribution business, while foreign currency in the quarter reduced 2016 adjusted gross profit by approximately $11 million. The Company exited the Belgium distribution business at the end of the fourth quarter 2016. Reported operating loss of $76 million was primarily impacted by an impairment charge of $34 million on Australian definite-lived intangible assets and restructuring charges of $10 million. Adjusted operating income was $36 million due to relatively lower gross profit dollar contribution and negative foreign currency movements of more than $5 million compared to the prior year, offset partially by lower advertising and promotion expenses. Reported net sales in the fourth quarter of 2016 were $266 million, an increase of 3% driven by $29 million related to product acquisitions and new product sales of $15 million, offset partially by a decrease in sales of existing products of $37 million due primarily to price erosion. Fourth quarter reported gross margin was 45.5%. Reported operating loss of $259 million was primarily impacted by a $342 million impairment charge specifically related to the Entocort® product. Adjusted gross profit was $149 million, while adjusted gross margin was relatively flat as the favorable effect of product acquisitions was offset by price erosion.  Adjusted operating margin of 43.2% increased 110 bps compared to the prior year primarily due to timing of R&D investments. As outlined in Footnote 1 on the 2016 Form 10-K, there are three primary impacts due to the restatement. 1) As restated, the Company has accounted for the Tysabri® royalty stream as a financial asset (rather than an intangible asset) and has elected to use the fair value option model. The Company made the election to account for the Tysabri® financial asset using the fair value option as it believes this method is most appropriate for an asset that does not have a par value, a stated interest stream, or a termination date. This accounting requires the Company to adjust its financial statements for the restated periods listed in its 2016 Form 10-K to (1) remove the Tysabri® royalty stream from net sales in its Consolidated Statements of Operations, (2) remove the amortization expense (reflected in cost of goods sold) associated with recording the Tysabri® royalty stream as an intangible asset, and (3) include the quarterly changes in fair value of the Tysabri® royalty stream as a component of other non-operating income/expense. The cash payments the Company received from the royalty stream are included in its Statements of Cash Flows for the restated periods and reflect the cash received from the Tysabri® royalty stream as cash from investing activities, rather than as cash from operating activities. 2) In connection with the financial closing for the year ended December 31, 2016, the Company identified certain tax basis intangible assets that existed at the time of the acquisition of Omega on March 30, 2015, which reduced the deferred tax liabilities in acquired intangible assets and increased our valuation allowance resulting in a net change to our deferred taxes of approximately $236 million. The resulting balance sheet reclassification required a reduction of goodwill, offset by a corresponding reduction to net deferred tax liabilities at the date of the Omega acquisition. Further, the Company has evaluated the accounting effect subsequent to the acquisition date related to the remeasured deferred tax liability, including the impairments of Omega goodwill recorded in 2016 and certain adjustments to valuation allowances, which have been reflected in the restated financial statements. 3) The Company corrected previously identified adjustments, which primarily related to certain contracts related to a specific Belgium distributor that were consignment in nature due to an option for the distributor to return the product if it was not sold timely. The characterization of the contracts as consignment impacted the timing of revenue recognition in the Consolidated Statement of Operations and, due to the impact on factoring arrangements, required a reclassification between accounts receivable and current liabilities for the amounts factored for these contracts. The total effect of previously identified adjustments, inclusive of the Belgium distributor adjustment, reduced 2016 net sales by approximately $3 million. The Company is now accounting for the Tysabri® royalty stream as a financial asset and has elected to use the fair value option model with changes in fair value presented in Net income (loss) under the caption Tysabri® royalty stream - change in fair value. In November 2016, we announced we were evaluating strategic alternatives for the Tysabri® asset. On March 27, 2017 the Company divested its rights to the Tysabri® royalty stream to Royalty Pharma for $2.2 billion in cash and additional milestone payments of up to $250 million and $400 million in royalties earned if global net sales of Tysabri® meet specific thresholds in 2018 and 2020, respectively. The effects of the announced strategic review and the sale completed on March 27, 2017 were taken into consideration in recording a $1.1 billion decrease in the fair value of the asset during the fourth quarter. During the fourth quarter of 2016, the Company identified indicators of goodwill impairment in the Specialty Sciences reporting unit related to its decision to review strategic alternatives for the rights to the Tysabri® royalty stream. As a result of the impairment indicators, the Company prepared a goodwill impairment test as of December 31, 2016. Step one of the goodwill impairment test indicated that the fair value of the Specialty Sciences reporting unit was below its net book value. As a result, the Company initiated the second step of the goodwill impairment test to measure the amount of impairment. The Company concluded that the goodwill was fully impaired and recorded an impairment of $200 million in Impairment charges on the Consolidated Statement of Operations within the Specialty Sciences segment. During the fourth quarter of 2016, the Company identified indicators of goodwill impairment in the Animal Health reporting unit related to changes in the market and performance of certain brands. The Company prepared a goodwill impairment test as of October 2, 2016 as part of its annual goodwill impairment testing process. Step one of the goodwill impairment test indicated that the fair value of the Animal Health reporting unit was below its net book value. As a result, the Company performed the second step of the goodwill impairment test to measure the amount of impairment. The Company concluded that Animal Health goodwill was impaired by $25 million, which was recorded in Impairment charges on the Consolidated Statement of Operations within the CHC Americas segment. During the fourth quarter of 2016, the Company identified impairment indicators in its Entocort® product assets which related to the entrance of new market competition and resulting negative impacts on sales volume and pricing. Utilizing a multi-period excess earnings method, the Company determined that the Entocort® product assets were impaired by $342 million. The impairment was recorded in Impairment charges on the Consolidated Statement of Operations within the RX segment. The Company also identified impairment indicators in certain definite-lived intangible assets in the CHC International reporting segment, including trademarks and trade names related to the Herron products originally acquired through the Aspen acquisition. After determining the assets were impaired, the Company utilized the relief from royalty method to quantify the impairment, resulting in a $31 million impairment. The Company recorded these impairments in Impairment charges on the Consolidated Statement of Operations within the CHC International segment. The Company expects 2017 net sales to be in the range of $4.6 billion to $4.8 billion, which assumes the cancellation of approximately $210 million of unprofitable distribution agreements in the CHC International business. The Company expects calendar year 2017 GAAP diluted EPS to be in the range of $0.22 to $0.57 (inclusive of income from the sale of the Tysabri® royalty stream) and adjusted diluted EPS to be in the range of $4.15 to $4.50, including contributions from API and excluding the charges outlined in Table IV at the end of this release. The Company plans to hold its 2017 annual general meeting of shareholders on July 20, 2017.  Shareholders of record on May 26, 2017, the record date for the meeting, will be entitled to vote at the meeting. Qualified stockholder proposals (including proposals made pursuant to Rule 14a-18 under the Securities Exchange Act of 1934) to be presented at the Annual Meeting and (if required pursuant to Rule 14a-8 under such Act) included in the Company's proxy statement and form of proxy relating to that meeting must be received by the Company's Secretary at Perrigo Company plc, Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland, not later than the close of business on June 2, 2017. Any proposal must comply with all applicable requirements, including applicable Irish law, the rules and regulations promulgated by the United States Securities and Exchange Commission, and the procedures set forth in the Company's Memorandum and Articles of Association. The Company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT), May 23, 2017. The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 877-248-9413, International 973-582-2737, and reference ID #23027414. A taped replay of the call will be available beginning at approximately 11:30 a.m. (ET) Tuesday, May 23, until midnight Tuesday, June 06, 2017. To listen to the replay, dial 800-585-8367, International 404-537-3406, and use access code 23027414. Perrigo remains in a quiet period until the Company files its first quarter 2017 Form 10-Q. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality, Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; our ability to achieve our guidance, and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting, may encounter unanticipated material issues or additional adjustments that could delay the filing of required periodic reports with the United States Securities and Exchange Commission, or may be unable to regain compliance with the NYSE continued listing rules. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operation, balance sheets or statements of cash flows of the company. Pursuant to the requirements the U.S. Securities and Exchange Commission, the Company has provided reconciliations for net sales on a constant currency basis, net sales excluding sales attributable to held-for-sale businesses, adjusted gross profit, adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted gross margin, and adjusted operating margin within this press release to the most directly comparable U.S. GAAP measures for these non-GAAP measures. These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies. The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe may obscure underlying business operational trends. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation. Non-GAAP measures related to profit measurements, which include adjusted gross profit, adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted gross margin, adjusted operating margin and adjusted diluted shares outstanding are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company discloses adjusted net sales, which excludes operating results attributable to held-for-sale businesses, in order to provide information about sales of the Company's continuing business. In addition, the Company discloses net sales growth and adjusted net sales growth on a constant currency basis to provide information about sales of the Company's continuing business excluding the exogenous impact of foreign exchange. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past, present and future underlying operating results, and also facilitate comparison of the Company's operating performance to the operating performance of its competitors. A copy of this press release, including the reconciliations, is available on the Company's website at www.perrigo.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/perrigo-files-2016-form-10-k-with-restated-financial-statements-reports-fourth-quarter-and-calendar-year-2016-financial-results-announces-2017-annual-meeting-date-300461804.html


"[The method] used for neonatal screening and obtaining dry blood samples, when a few blood drops are applied to special cellulose carriers and then dried in air, requires special cards not produced in Russia, as well as expensive specialized equipment for obtaining samples of biomaterial for further analysis. And this technology doesn't even exist in every major city. Additionally, the difficulty of using such carriers for quantitative analysis of animal and human blood is caused by irregularity of its diffusion on carriers due to the complex structure of cellulose and the presence of inconvertible adsorption of blood components, which greatly distorts the results of analysis," said Associate Professor Alexander Osipov, one of developers of the project, a Candidate of Chemical Sciences, and a senior research assistant at NUST MISIS Department of Functional Nanosystems. That is why at the present time, special medial syringes-vials for gathering liquid samples of blood or serum and delivered to laboratories for analysis in special containers with special temperature conditions (often frozen) are used in medical and veterinary diagnosis. The whole process is quite expensive and inconvenient. In addition, if a violation of temperature or time conditions occurs during the delivery or storage, blood samples lose their properties, possibly leading to incorrect results. This problem was solved by replacing the cellulose with specially-prepared porous inorganic material containing nanoparticles of metals. Scientists managed to choose the composition and form of the absorbent so the blood was evenly distributed throughout the volume, and upon washing the analyzed blood components it almost completely passed into solution. Modified samples dry about 2 times faster, which critically speeds up sample preparation process. To transport to a laboratory, the card is put in an envelope and sent by mail without need of special transport, which leads to significant financial savings. For example, in past events of an emergency epidemiological situation - like the outbreak of the Siberian plague in Yamal in 2016 - the cost of express delivery of a batch of biomaterials to a Moscow lab amounted to several million rubles. The cost of the card itself in manual small-scale wholesale production is five times lower than industrial imported cellulose: 40 Rubles against 180 Rubles. When considering large-scale production the price will be even lower. Now the creators of the new patented technology of sample preparation have decided to focus on veterinary diagnosis, because in animal breeding and farming there is a need to conduct hundreds of thousands of tests, but there are no conditions for these tests on farms located in remote areas. The Federal Center for Animal Health (FGBI «ARRIAH») has become the main partner of the practical approbation of the proposed technology (Russia, Vladimir). Now scientists are collaborating with some of Russia`s largest poultry and animal farms, which determines the level of bird immunity, vaccinations, the presence of the FMD virus, rabies, leukemia, and other particularly dangerous infections animals may have. After the completion of testing and certification procedures, it will be possible to start the serial production of a pilot series of membrane carriers of the new model for sample selection. According to preliminary estimates, all necessary documents will be ready by the end of 2017. There are now negotiations being conducted with the leading Russian diagnostic laboratories for use of the new technology in medical diagnostics, including screenings for communicable diseases such as hepatitis, HIV, and others. In addition, several large companies from Southeast Asia have also expressed interest in using the new system both in veterinary and medical diagnostics. The system was developed through the framework of the Federal Target Program «Research and developments in priority areas of advancement of the Russian scientific and technological complex for 2014-2020» (Agreement № 14.578.21.0010) with the support of the Russian Ministry of Science and Education.


"[The method] used for neonatal screening and obtaining dry blood samples, when a few blood drops are applied to special cellulose carriers and then dried in air, requires special cards not produced in Russia, as well as expensive specialized equipment for obtaining samples of biomaterial for further analysis. And this technology doesn't even exist in every major city. Additionally, the difficulty of using such carriers for quantitative analysis of animal and human blood is caused by irregularity of its diffusion on carriers due to the complex structure of cellulose and the presence of inconvertible adsorption of blood components, which greatly distorts the results of analysis," said Associate Professor Alexander Osipov, one of developers of the project, a Candidate of Chemical Sciences, and a senior research assistant at NUST MISIS Department of Functional Nanosystems. That is why at the present time, special medial syringes-vials for gathering liquid samples of blood or serum and delivered to laboratories for analysis in special containers with special temperature conditions (often frozen) are used in medical and veterinary diagnosis. The whole process is quite expensive and inconvenient. In addition, if a violation of temperature or time conditions occurs during the delivery or storage, blood samples lose their properties, possibly leading to incorrect results. This problem was solved by replacing the cellulose with specially-prepared porous inorganic material containing nanoparticles of metals. Scientists managed to choose the composition and form of the absorbent so the blood was evenly distributed throughout the volume, and upon washing the analyzed blood components it almost completely passed into solution. Modified samples dry about 2 times faster, which critically speeds up sample preparation process. To transport to a laboratory, the card is put in an envelope and sent by mail without need of special transport, which leads to significant financial savings. For example, in past events of an emergency epidemiological situation - like the outbreak of the Siberian plague in Yamal in 2016 - the cost of express delivery of a batch of biomaterials to a Moscow lab amounted to several million rubles. The cost of the card itself in manual small-scale wholesale production is five times lower than industrial imported cellulose: 40 Rubles against 180 Rubles. When considering large-scale production the price will be even lower. Now the creators of the new patented technology of sample preparation have decided to focus on veterinary diagnosis, because in animal breeding and farming there is a need to conduct hundreds of thousands of tests, but there are no conditions for these tests on farms located in remote areas. The Federal Center for Animal Health (FGBI «ARRIAH») has become the main partner of the practical approbation of the proposed technology (Russia, Vladimir). Now scientists are collaborating with some of Russia`s largest poultry and animal farms, which determines the level of bird immunity, vaccinations, the presence of the FMD virus, rabies, leukemia, and other particularly dangerous infections animals may have. After the completion of testing and certification procedures, it will be possible to start the serial production of a pilot series of membrane carriers of the new model for sample selection. According to preliminary estimates, all necessary documents will be ready by the end of 2017. There are now negotiations being conducted with the leading Russian diagnostic laboratories for use of the new technology in medical diagnostics, including screenings for communicable diseases such as hepatitis, HIV, and others. In addition, several large companies from Southeast Asia have also expressed interest in using the new system both in veterinary and medical diagnostics. The system was developed through the framework of the Federal Target Program «Research and developments in priority areas of advancement of the Russian scientific and technological complex for 2014-2020» (Agreement № 14.578.21.0010) with the support of the Russian Ministry of Science and Education.


News Article | May 25, 2017
Site: www.businesswire.com

ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies, Inc. (Nasdaq: PDCO) today reported consolidated net sales of $1.4 billion (see attached Sales Summary for further details) in its fiscal fourth quarter ended April 29, 2017, essentially flat compared to the same period last year. Adjusting for the effects of currency translation, sales improved 0.8 percent. Reported net income from continuing operations was $61.4 million, or $0.65 per diluted share, compared to $65.6 million, or $0.68 per diluted share, in last year’s fiscal fourth quarter. Adjusted net income1 from continuing operations, which excludes certain non-recurring items and deal amortization costs, totaled $65.6 million for the fourth quarter of fiscal 2017, down 11.4 percent from $74.1 million in the same quarter last year. Adjusted earnings1 per diluted share from continuing operations totaled $0.69 in the 2017 fourth quarter, down 10.4 percent year-over-year. “ Patterson Companies continues to move through a period of strategic investment and change, responding to the evolving needs of our customers and implementing an enterprise resource planning system to modernize our technology infrastructure for future capabilities. While we have made tremendous progress on these initiatives, our fiscal 2017 financial performance does not reflect the strength of the platform we are building,” said Scott Anderson, chairman, president and CEO of Patterson Companies. “ During fiscal 2018, we will be implementing a range of necessary actions to improve our execution and margin profile. In addition to our enterprise-wide efficiency programs, these actions will include sales and marketing investments in our Dental segment and continued synergy capture in our Animal Health segment. We believe our existing strategies, supported by these additional actions, will minimize short-term headwinds and enhance the longer-term strength of our business.” Patterson Dental Reported net sales in our Dental segment, which represented approximately 42 percent of total company sales, were $607.3 million, down 8.3 percent from the same quarter last year. Sales declined 8.2 percent on a constant currency basis from the fiscal 2016 fourth quarter. On that same basis, year-over-year sales by category were as follows: “ In fiscal 2017, we took the important steps in our Dental segment to evolve our sales approach and broaden our future digital technology portfolio to respond to changing customer needs and serve a wider range of clinical environments. We are confident in these strategies, but recognize that they impacted near-term sales execution,” added Anderson. “ Consumable sales during the fourth quarter were directly impacted by these actions. In the months ahead, we intend to make incremental investments within our sales and marketing approach to improve execution. We are fully committed to improving our growth and margin profile in Dental and believe that these efforts, along with the addition of new digital technologies, will allow us to capitalize on our unique competitive strengths and the many market opportunities ahead.” Patterson Animal Health Fourth-quarter reported net sales for Patterson Animal Health, which comprised approximately 58 percent of the company’s total sales, were $827.5 million, 6.0 percent higher than last year’s fourth quarter. Sales increased 8.6 percent on a constant currency basis from the fiscal 2016 fourth quarter. On that same basis, year-over-year sales by category were as follows: “ Patterson Animal Health has a strong and growing market position in North America. While this segment generated improved sales during the fourth quarter, we believe there is room for greater profit contribution from this business,” continued Anderson. “ During fiscal 2017, we began to take important steps forward in this area through marketing and sales execution. We remain disciplined in our commitment to synergy capture to fully realize the strengths of our combined animal health platform.” Discontinued Operations On August 28, 2015, Patterson Companies completed the sale of Patterson Medical to Madison Dearborn Partners for approximately $717 million. As a result of the sale, Patterson Medical is classified and reported as discontinued operations for all periods presented. Share Repurchases and Dividends For the full fiscal year, Patterson repurchased approximately 2.9 million shares of its outstanding common stock, with a value of $125.4 million, leaving approximately 13.6 million shares for repurchase under the current authorization, which expires in March 2018. The company also paid $25.0 million in cash dividends to shareholders in the fourth quarter and $95.9 million in cash dividends to shareholders during fiscal 2017. Full-Year Results1 Reported net sales for fiscal 2017 totaled $5.6 billion, a 3.8 percent increase from fiscal 2016. Adjusting for the effects of currency translation and the extra week in the prior fiscal-year period, sales for the year grew 6.5 percent. Sales grew 2.9 percent when excluding the additional six-week impact of Animal Health International, Inc. Reported net income from continuing operations was $173.8 million, or $1.82 per diluted share, compared to $185.7 million, or $1.90 per diluted share last year. Adjusted net income1 from continuing operations, totaled $223.3 million, or $2.34 per diluted share, compared to adjusted net income1 from continuing operations of $241.4 million, or $2.47 per diluted share last year. Reported net income from continuing operations and adjusted net income1 from continuing operations in fiscal 2017 also include the previously disclosed pre-tax step-up in enterprise resource planning expenses of approximately $25 million. As noted above, sales in the prior fiscal year included an extra sales week and approximately six fewer weeks of contribution from Animal Health International, Inc. Business Outlook Anderson concluded, “ Since we set out on our strategic path in 2015 to rebalance our business portfolio, modernize our IT platform and sharpen our go-to-market approach, Patterson Companies has made significant progress. We expect that the key decisions we made and actions we took during fiscal 2017 will lead to lasting, positive impacts. However, we expect the headwinds of these investments and initiatives to extend into our current fiscal year. As we enter fiscal 2018, we are encouraged by: market stability across our businesses; the maturing of our ERP implementation process and our ability to effectively use this system to drive our business; the new wave of digital technology we expect to be coming to market in our Dental segment; and disciplined synergy capture in Animal Health. We are optimistic about Patterson Companies’ long-term growth prospects and the returns these investments will bring to our customers, employees and shareholders.” Fiscal 2018 Guidance Patterson today established its fiscal 2018 earnings guidance from continuing operations, which is provided on both a GAAP and non-GAAP adjusted1 basis: Our guidance is for current continuing operations as well as completed or previously announced acquisitions and does not include the impact of potential future acquisitions or similar transactions, if any, or impairments and material restructurings beyond those previously publicly disclosed. Our guidance assumes North American and international market conditions similar to those experienced in fiscal 2017. The Reconciliation of GAAP to non-GAAP Measures table appearing behind the accompanying financial information is provided to adjust reported GAAP measures, namely earnings from continuing operations, net income from continuing operations, and earnings per diluted share from continuing operations, for the impact of transaction related costs, deal amortization, intangible asset impairment, integration and business restructuring expenses, accelerated debt issuance costs and discrete tax matters. Management believes that these non-GAAP measures may provide a helpful representation of the company’s fourth quarter and full year performance, and enable comparison of financial results between periods where certain items may vary independent of business performance. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. In addition, the term constant currency used in this release represents net sales adjusted to exclude foreign currency impacts. Foreign currency impact represents the difference in results that is attributable to fluctuations in currency exchange rates the company uses to convert results for all foreign entities where the functional currency is not the U.S. dollar. The company calculates the impact as the difference between the current period results translated using the current period currency exchange rates and using the comparable prior period’s currency exchange rates. The company believes the disclosure of net sales changes in constant currency provides useful supplementary information to investors in light of significant fluctuations in currency rates. Fourth-Quarter Conference Call and Replay Patterson’s fourth-quarter earnings conference call will start at 10 a.m. Eastern today. Investors can listen to a live webcast of the conference call at www.pattersoncompanies.com. The conference call will be archived on Patterson’s website. A replay of the fiscal 2017 fourth-quarter conference call can be heard for one week at 888-203-1112 and by providing the Conference ID 8211258 when prompted. About Patterson Companies, Inc. Patterson Companies, Inc. is a value-added distributor serving the dental and animal health markets. Dental Market Patterson's Dental segment provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America. Animal Health Market Patterson's Animal Health segment is a leading distributor of products, services and technologies to both the production and companion animal health markets in North America and the U.K. This press release contains certain forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are information of a non-historical nature and are subject to risks and uncertainties that are beyond Patterson's ability to control. Forward-looking statements generally can be identified by words such as "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on the results of operations and financial condition of Patterson or the price of Patterson stock. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including but not limited to the other risks and important factors contained and identified in Patterson's filings with the Securities and Exchange Commission, such as its Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, any of which could cause actual results to differ materially from the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except to the extent required under the federal securities laws, Patterson does not intend to update or revise the forward-looking statements.


News Article | May 25, 2017
Site: www.prnewswire.com

NEW YORK, May 25, 2017 /PRNewswire/ -- Description Welcome to the Global Animal Health Partnering Terms and Agreements 2010 to 2017 report. The report provides a detailed understanding and analysis of how and why companies enter Animal Health partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Animal Health agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Animal Health deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Animal Health partnering deals. The report presents financial deal term values for Animal Health deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Animal Health partnering field; both the leading deal values and most active Animal Health dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 400 online deal records of actual Animal Health deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of Animal Health dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Animal Health dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading Animal Health deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in Animal Health dealmaking with a brief summary followed by a comprehensive listing of Animal Health deals announded by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of Animal Health partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of Animal Health partnering deals signed and announced since Jan 2010. The chapter is organized by specific Animal Health technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by Animal Health partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Animal Health partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Animal Health technologies and products. Key benefits Global Animal Health Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits: - In-depth understanding of Animal Health deal trends since 2010 - Access to headline, upfront, milestone and royalty data - Analysis of the structure of Animal Health agreements with real life case studies - Detailed access to actual Animal Health contracts entered into by leading biopharma companies - Identify most active Animal Health dealmakers since 2010 - Insight into terms included in a Animal Health partnering agreement, with real world examples - Understand the key deal terms companies have agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Animal Health Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Animal Health trends and structure of deals entered into by leading companies worldwide. Animal Health Partnering Terms and Agreements includes: - Trends in Animal Health dealmaking in the biopharma industry since 2010 - Analysis of Animal Health deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life Animal Health deals - Access to Animal Health contract documents - Leading Animal Health deals by value since 2010 - Most active Animal Health dealmakers since 2010 In Global Animal Health Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Specific therapy target - Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Animal Health Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 400 Animal Health deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How aresalesand payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Read the full report: http://www.reportlinker.com/p03951353-summary/view-report.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com   __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-animal-health-partnering-terms-and-agreements-2010-to-2017-300464187.html

Loading Animal Health collaborators
Loading Animal Health collaborators